A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth
Katie Streicher(AstraZeneca (United States)), Yandan Yao(Sun Yat-sen University), Zhenna Xiao, Laura K. Richman(University of Pennsylvania), Philip Z. Brohawn(Hofstra University), Kim Lehmann, Rosa A. Carrasco, Bahija Jallal(Unknown), Robert W. Georgantas, Wei Zhu(Ministry of Education of the People's Republic of China), DA Tice, Christopher Morehouse, K. Ranade, Brandon W. Higgs(Parker Institute for Cancer Immunotherapy)
Cited by 135
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|Cell|2020|546
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478
MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
|Clinical Cancer Research|2009|435
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412